NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI LO (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Viatris is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ]. First approved in 2018.
Drug data last refreshed 26m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI LO is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for oral treatment of HIV-1 infection. The three-drug combination provides complementary antiviral mechanisms to suppress HIV-1 replication. It is designed for treatment-naïve and treatment-experienced patients requiring a simplified, single-tablet regimen.
$0.135MPart D
PeakStable
Peak lifecycle stage with modest Part D utilization indicates mature market position with stable but limited growth opportunity for commercial expansion.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYMFI LO careers focus on defending market share and optimizing reimbursement in a mature, competitive HIV treatment category. Roles emphasize sales execution, payer relations, and medical support rather than early-stage development or innovation.
Brand ManagerMarket Access Specialist
Worked on SYMFI LO at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.